Database containing demographic data of each patient and laboratory data of each patient and control

<p>This file contains raw data of all laboratory measurements presented in the paper. In addition, the file contains raw demographic data of the patients as summarized in the paper in Table 1.</p

Reductions in ETP after the addition of the different anticoagulant drugs.

<p>Reduction in ETP after the addition of (A) dabigatran, (B) heparin, (C) LMWH, (D) Fondaparinux, and (E) rivaroxaban in plasma from patients with Child A, B, and C cirrhosis and healthy controls. Bars indicate medians with the error bars representing interquartile ranges. ** = P<0.01 compared to controls.</p

Correlation between FX levels and reductions in thrombin generation after rivaroxaban.

<p>Correlation between plasmatic FX levels and the percentual reduction in peak thrombin generation when tested in the presence of TM after addition of rivaroxaban at 25 ng/ml in plasma from patients with cirrhosis.</p

Demographic and clinical characteristics of the study population.

<p>HCV: Hepatitis C virus, NASH: Non-alcoholic steatohepatitis, PBC: Primary biliary cirrhosis, PSC: Primary sclerosing cholangitis, DM: Diabetes Mellitus.</p><p>Data are expressed as number (%), mean [SD], or median [range].</p

Coagulation parameters in cirrhotic patients and controls.

<p>INR: International normalized ratio, AT: Antithrombin.</p><p>Data are expressed as median [range].</p

Correlation between AT/FX levels and reductions in thrombin generation after fondaparinux.

<p>Correlation between the percentual reduction in ETP when tested in the presence of TM after addition of 0.5 µg/ml fondaparinux and <b>(A)</b> plasmatic AT levels and <b>(B)</b> plasmatic FX levels in plasma from patients with cirrhosis.</p

Correlation between FII levels and reductions in thrombin generation after dabigatran.

<p>Correlation between plasmatic FII levels and percentual reduction of peak thrombin values when tested in the presence of TM after addition of 300/ml dabigatran in plasma from patients with cirrhosis.</p

Inhibition of in vitro thrombin generation after addition of various anticoagulant drugs to plasma taken from patients with cirrhosis or plasma from healthy controls.

<p>TM: thrombomodulin, ETP: Endogenous thrombin potential, Velindex: velocity index, LMWH: low molecular weight heparin.</p><p>Shown are the percentual inhibition of the ETP, peak, or velocity index, and the percentual increase in the lag time. Data are expressed as median percentages with interquartile range.</p>*<p> = P<0.05, ** = P<0.01 compared to controls.</p

Clinical and laboratory characteristics in subjects with and without non-alcoholic fatty liver disease estimated by the Fatty Liver Index (FLI ≥ 60).

<p>Clinical and laboratory characteristics in subjects with and without non-alcoholic fatty liver disease estimated by the Fatty Liver Index (FLI ≥ 60).</p

Multivariable logistic regression analyses demonstrating independent associations of non-alcoholic fatty liver disease estimated by the Fatty Liver Index (FLI ≥ 60) with current smoking, HbA1c and type 2 diabetes mellitus.

<p>Multivariable logistic regression analyses demonstrating independent associations of non-alcoholic fatty liver disease estimated by the Fatty Liver Index (FLI ≥ 60) with current smoking, HbA1c and type 2 diabetes mellitus.</p